Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

BPRMU191

  Cat. No.:  DC76604  
Chemical Structure
2131199-52-3
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biased MOR agonists, thereby inducing MOR-dependent activation and analgesic effects. Co-administration of BPRMU191 with morphinan antagonists provides analgesia while reducing side effects such as gastrointestinal dysfunction, antinociceptive tolerance, and dependency-related adverse effects. BPRMU191, in combination with morphinan antagonists, offers a potential strategy for studying severe pain management and G protein-coupled receptor modulation.
Chemicals PropertiesBiological activity Related products COA MSDS Datasheet
Cas No.: 2131199-52-3
Chemical Name: BPRMU191
SMILES: O=C(C1=CC=C(N2C(CSC2C3=CC=C(C=C3)F)=O)C(C)=C1)O
Formula: C17H14FNO3S
M.Wt: 331.36
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Cat. No. Product name Field of application
DC72634 (Rac)-SNC80 (Rac)-SNC80 is a racemate of SNC80. SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment.
DC46693 DAMGO DAMGO (DAGO) is a potent and selective μ opioid receptor agonist with ki of 17 nM.
DC44976 LY2940094 tartrate LY2940094 (BTRX-246040) tartrate is a potent, brain penetrant, selective and orally available N/OFQ peptide (NOP) receptor antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 tartrate reduces Ethanol self-administration and Ethanol seeking in animal models.
DC41767 Nociceptin(1-7) TFA Nociceptin (1-7) TFA is the N-terminal bioactive fragment of nociceptin. Nociceptin (1-7) TFA is a potent ORL1 (NOP) receptor agonist with antinociceptive activity. Nociceptin (1-7) TFA combines with nociceptin reduces hyperalgesia in vivo.
DC41766 Nociceptin(1-7) Nociceptin (1-7) is the N-terminal bioactive fragment of nociceptin. Nociceptin (1-7) is a potent ORL1 (NOP) receptor agonist with antinociceptive activity. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia in vivo.
DC40982 Loperamide phenyl Loperamide phenyl is an impurity of Loperamide. Loperamide is an opioid receptor agonist.
DC28780 LY2444296 LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ∼1 nM. LY2444296 exhibits anti-anxiety like effects.
DC10290 PZM21 PZM21 is a potent and selective μ opioid receptor agonist with an EC50 of 1.8 nM.
DC9527 Methylnaltrexone (Bromide) Methylnaltrexone Bromide is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation.
DC9526 Meptazinol (hydrochloride) Meptazinol Hcl(WY-22811 Hcl) is a unique centrally active opioid analgesic.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia